


HF-POLARIS

zenagamtide | effects on heart failure outcomes in people with obesity

National Data Package



National Leader:




Nicolas Girerd

Participant overview

Participant overview	Overall recruitment target	Participants screened	Participants randomised	Screen failure rate*	Off treatment
	N	N	N	%	N
France	30	7	6	14	0
Global	5,610	1,064	438	46	12

*Forecasted

Participants randomised and recruitment target in France in 2026



Screen failure reasons

Screen failure reasons	France	Global*
	N (%)	N (%)
NT-proBNP (I7)	0 (0)	153 (38)
HF decompensation/ eGFR/UACR (I8)	1 (100)	104 (26)
Investigator discretion (E31)	0 (0)	22 (5)
HbA _{1c} >10% (E12)	0 (0)	12 (3)
LVEF (I5)	0 (0)	12 (3)
Diabetic retinopathy (E10)	0 (0)	10 (3)
ICF process (I1)	0 (0)	8 (2)
BMI (I3)	0 (0)	8 (2)
Malignancy history (E22)	0 (0)	7 (2)
Insulin therapy (E11)	0 (0)	6 (2)
Other	0 (0)	64 (16)

*Globally, 34 participants (13%) failed due to more than one eligibility criteria

BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA_{1c}, glycated haemoglobin; HF, heart failure; ICF, Informed Consent Form; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal B-type natriuretic peptide.

Site*	PI	Participants, N			
		Screened	In screening	Screen failed	Randomised
2402	Fabrice Ivanes	1	0	0	1
2406	Jean-Michel Tartière	2	0	0	2
2409	Jean-Etienne RICCI	3	0	1	2
2410	Jean-Noël Labeque	1	0	0	1

Notes



Notes

What are the challenges you face or anticipate facing concerning:



Recruitment?



Retention?



Collaboration with other stakeholders?

Are there any challenges in other areas that you'd like to address in your action plan?

What actions or initiatives can you implement to help resolve these issues?
